Markets

Biotech IPOs Focused on NASH

After years of disappointing clinical trials for nonalcoholic steatohepatitis (NASH), an often fatal liver disease associated with obesity and diabetes, there are a number of promising late-stage clinical trials underway, including two being conducted by pending biotechs Cirius Therapeutics ( CSTX ) and Genfit ( GNFT ). NASH affects 20 million people with no FDA-approved therapies and is a multi-billion dollar opportunity.

Cirius recently reported positive interim results in a Phase 2 trial for its once daily oral small molecule that is a selective modulator of mitochondrial metabolism. It has enrolled a Phase 2b trial that will be the basis for designing a larger pivotal trial...

To read the entire article, sign up for a free 7-day trial of IPO Pro, the single, most effective IPO data platform you'll ever need.

Start a Free Trial of IPO Pro

The article Biotech IPOs Focused on NASH originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos